Fresenius Medical will acquire all of NxStage’s outstanding shares valued a $30 per share, or about $2 billion.
NxStage’s board approved the transaction. The deal is subject to approval from NxStage stockholders, regulatory approvals and additional closing conditions.
Fresenius projects the transaction will close in 2018.
More articles on transactions and valuation:
Piedmont Healthcare opens 27 retail clinics in Atlanta Walgreens stores
Baylor Scott & White now co-owner of Texas Spine & Joint Hospital
University of Chicago Medicine partners with Community Hospital of Indiana to treat high-risk pregnancies
